Vyvanse Cognitive Function Impact: What the Clinical Evidence Actually Shows

What the evidence actually measures

The ADHD trials that support Vyvanse did not give participants a neuropsychological battery. They scored symptoms with the ADHD Rating Scale (ADHD-RS), classroom behaviour with the SKAMP scale, and task performance with the Permanent Product Measure of Performance (PERMP) [1][2][3]. One college-student study added self-report rating scales of functioning, including executive function, and a direct assessment of verbal learning and memory [5].

The label states that the exact mode of therapeutic action in ADHD and binge eating disorder is not known [4]. Lisdexamfetamine itself is inactive. It is converted to dextroamphetamine mainly in red blood cells, not by cytochrome P450 enzymes, and amphetamines block reuptake of norepinephrine and dopamine and increase release of both [4].

What the ADHD trials found

Children aged 6 to 12. A phase 3 trial at 40 US centres randomised 290 children to lisdexamfetamine 30, 50 or 70 mg or placebo for 4 weeks with forced-dose titration. All three doses improved ADHD-RS-IV scores more than placebo. Discontinuations for adverse events were 9% at 30 mg, 5% at 50 mg, 14% at 70 mg and 1% on placebo [1].

Adults. A 4-week trial randomised 420 adults aged 18 to 55. Change in ADHD-RS total score at endpoint was -8.2 on placebo, -16.2 at 30 mg, -17.4 at 50 mg and -18.6 at 70 mg, all p<.0001 versus placebo, with no differences between doses. A Clinical Global Impressions-Improvement rating of 2 or better was reached by 29% on placebo versus 57%, 62% and 61% at 30, 50 and 70 mg [2].

Adolescents aged 13 to 17. In a 4-week forced-dose trial of 314 participants, ADHD-RS-IV change was -18.3 at 30 mg, -21.1 at 50 mg and -20.7 at 70 mg versus -12.8 on placebo, p≤.0056 for each dose. 69.1% of treated participants were rated much or very much improved versus 39.5% on placebo [6].

All three trials ran 4 weeks. Symptom ratings over four weeks answer a narrower question than whether attention or memory holds up over a year of treatment.

The closest thing to a cognitive test

A timed classroom study in children. This phase 2 randomised, double-blind, placebo- and active-controlled crossover study gave 52 children aged 6 to 12 lisdexamfetamine 30, 50 or 70 mg, placebo, or mixed amphetamine salts extended-release 10, 20 or 30 mg as a reference arm. Lisdexamfetamine significantly improved SKAMP-deportment, SKAMP-attention, PERMP-attempted, PERMP-correct and CGI-improvement scores from baseline [3]. One small crossover study of this kind shows that performance on short, timed classroom tasks improved with treatment. It does not show an effect on memory, learning or reasoning outside that setting.

College students with ADHD. Twenty-four students with ADHD, plus 26 students without psychopathology assessed at baseline only, went through five weekly phases: no drug, placebo, and lisdexamfetamine 30, 50 and 70 mg per day. The drug produced large reductions in ADHD symptoms and improvement in executive functioning, with smaller effects on psychosocial functioning. 86.4% of participants had a reduction in ADHD symptoms. Large differences in symptoms and executive functioning remained between the students with ADHD and the comparison group [5].

Does Vyvanse improve memory?

Verbal learning and memory were directly assessed in the 24-student study, but the abstract reports results for ADHD symptoms and executive functioning, not memory scores [5]. The large trials in children and adults used symptom rating scales rather than memory tests [1][2]. Whether lisdexamfetamine raises memory test scores in ADHD therefore cannot be answered from these reports.

Does a higher dose improve thinking more?

The label starts at 30 mg once every morning and allows adjustments of 10 or 20 mg at about weekly intervals to a recommended 30 to 70 mg per day, maximum 70 mg [4]. In the 420-adult trial, 30, 50 and 70 mg all beat placebo on ADHD-RS scores with no significant differences between the three doses [2]. The dose comparisons reported from these trials are symptom ratings, not cognitive test scores, so they give no dose-response curve for attention or memory specifically.

What about people without ADHD?

The trials above enrolled people with ADHD. A 2025 meta-analysis of 93 randomised trials of methylphenidate, lisdexamfetamine and other amphetamines did include trials in healthy individuals, but it assessed safety, not cognition. Across all populations, stimulants were associated with a higher risk of any adverse event than placebo (risk ratio 1.34, 90% CI 1.27 to 1.41), and the finding held separately for lisdexamfetamine [7].

The Vyvanse label carries a boxed warning for abuse, misuse and addiction, which can lead to a substance use disorder and, with misuse, overdose and death [4]. CNS stimulants raise blood pressure by a mean of about 2 to 4 mm Hg and heart rate by about 3 to 6 bpm, with larger rises in some patients [4]. New psychotic or manic symptoms occurred in about 0.1% of stimulant-treated patients versus 0% on placebo in pooled short-term trials [4].

Binge eating disorder: cognition was not the endpoint

The two pivotal binge eating disorder trials in adults measured binge eating days per week, and a separate trial measured relapse; none used cognitive tests. Lisdexamfetamine 50 or 70 mg per day reduced binge eating days per week by 1.35 days more than placebo in study 1 (95% CI -1.70 to -1.01) and by 1.66 days more in study 2 (95% CI -2.04 to -1.28), both P<0.001 [8]. In the randomised-withdrawal trial, relapse occurred in 3.7% of participants who continued lisdexamfetamine (5 of 136) versus 32.1% who switched to placebo (42 of 131), hazard ratio 0.09 (95% CI 0.04 to 0.23, P<.001) [9].

Time course: what the pharmacokinetics show

After a capsule, lisdexamfetamine peaks at about 1 hour and dextroamphetamine at about 3.5 hours in fasting children aged 6 to 12. Food delays the dextroamphetamine peak by about 1 hour without changing total exposure or peak concentration. Dextroamphetamine half-life is about 10 to 11.3 hours in healthy adults and 8.6 to 9.5 hours in children aged 6 to 12 [4]. In 12 healthy adults taking 70 mg daily, steady state gave a median time to peak of 3.0 hours, and 95% of dextroamphetamine was eliminated within 48 hours of the final dose [10].

The label directs morning dosing and says to avoid afternoon doses because of the potential for insomnia [4]. These are plasma measurements; they describe how long the drug is present, not how long any particular cognitive effect lasts.

What to watch for

The Vyvanse label gives adverse reaction rates from the 4-week trials. In adults with ADHD, insomnia occurred in 27% on lisdexamfetamine versus 8% on placebo, decreased appetite in 27% versus 2% and dry mouth in 26% versus 3% [4]. In children aged 6 to 12, decreased appetite occurred in 39% versus 4%, insomnia in 22% versus 3% and weight decrease in 9% versus 1% [4].

The label also lists peripheral vasculopathy including Raynaud's phenomenon, motor and verbal tics and worsening of Tourette's syndrome, and serotonin syndrome when combined with serotonergic drugs such as SSRIs, SNRIs, triptans, tramadol, lithium and St John's wort [4]. MAOIs are contraindicated during treatment and for 14 days after stopping one [4]. In severe renal impairment (GFR 15 to <30) the label sets a maximum of 50 mg per day, and in end-stage renal disease 30 mg per day [4].